Citations (48)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Youhoon Chong & Hyunah Choo. (2010) 5-HT3 antagonists under development. Expert Opinion on Investigational Drugs 19:11, pages 1309-1319.
Read now
Read now
Andrew J Thompson & Sarah CR Lummis. (2007) The 5-HT3 receptor as a therapeutic target. Expert Opinion on Therapeutic Targets 11:4, pages 527-540.
Read now
Read now
M. B. Hansen, F. Arif, L. Wallin & J. F. Pedersen. (2006) Serotonin and superior mesenteric artery resistance index. Scandinavian Journal of Clinical and Laboratory Investigation 66:5, pages 395-406.
Read now
Read now
Articles from other publishers (45)
Lakshmi Satish Kumar, Lakshmi Sree Pugalenthi, Mahlika Ahmad, Sanjana Reddy, Zineb Barkhane & Jalal Elmadi. (2022) Probiotics in Irritable Bowel Syndrome: A Review of Their Therapeutic Role. Cureus.
Crossref
Crossref
Muhammad Aziz, Jaya Kumar, Khairul Muhammad Nawawi, Raja Raja Ali & Norfilza Mokhtar. (2021) Irritable Bowel Syndrome, Depression, and Neurodegeneration: A Bidirectional Communication from Gut to Brain. Nutrients 13:9, pages 3061.
Crossref
Crossref
Gustavo R. Villas-Boas, Stefânia N. Lavorato, Marina M. Paes, Pablinny M. G. de Carvalho, Vanessa C. Rescia, Mila S. Cunha, Manoel F. de Magalhães-Filho, Luis F. Ponsoni, Adryano Augustto Valladao de Carvalho, Roseli B. de Lacerda, Lais da S. Leite, Matheus da S. Tavares-Henriques, Luiz A. F. Lopes, Luiz G. R. Oliveira, Saulo E. Silva-Filho, Ana P. S. da Silveira, Roberto K. N. Cuman, Francielli M. de S. Silva-Comar, Jurandir F. Comar, Luana do A. Brasileiro, Jussileide N. dos Santos, William R. de Freitas, Katyuscya V. Leão, Jonatas G. da Silva, Raphael C. Klein, Mary H. F. Klein, Bruno H. da S. Ramos, Cristiane K. C. Fernandes, Dayane G. de L. Ribas & Silvia A. Oesterreich. (2021) Modulation of the Serotonergic Receptosome in the Treatment of Anxiety and Depression: A Narrative Review of the Experimental Evidence. Pharmaceuticals 14:2, pages 148.
Crossref
Crossref
Aiya Aboubakr & Michelle S. Cohen. (2021) Functional Bowel Disease. Clinics in Geriatric Medicine 37:1, pages 119-129.
Crossref
Crossref
Albert Orock, Tian Yuan & Beverley Greenwood-Van Meerveld. (2021) Importance of Non-pharmacological Approaches for Treating Irritable Bowel Syndrome: Mechanisms and Clinical Relevance. Frontiers in Pain Research 1.
Crossref
Crossref
Daniel Hoyer. (2020) Targeting the 5-HT system: Potential side effects. Neuropharmacology 179, pages 108233.
Crossref
Crossref
Azadeh Seddighnia, Borna Tadayon Najafabadi, Kiandokht Ghamari, Ahmad Ali Noorbala, Naser Ebrahimi Daryani, Ladan Kashani & Shahin Akhondzadeh. (2019) Vortioxetine effects on quality of life of irritable bowel syndrome patients: A randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Pharmacy and Therapeutics 45:1, pages 97-104.
Crossref
Crossref
Biljana Radovanovic-Dinic, Snezana Tesic-Rajkovic, Sasa Grgov, Gordana Petrovic & Valentina Zivkovic. (2018) Irritable bowel syndrome - from etiopathogenesis to therapy. Biomedical Papers 162:1, pages 1-9.
Crossref
Crossref
Teita Asano, Ken-ichiro Tanaka, Arisa Tada, Hikaru Shimamura, Rikako Tanaka, Hiroki Maruoka, Mitsuko Takenaga & Tohru Mizushima. (2017) Aminophylline suppresses stress-induced visceral hypersensitivity and defecation in irritable bowel syndrome. Scientific Reports 7:1.
Crossref
Crossref
Jasmeet S. Mokha & Jeffrey S. Hyams. 2017. Pediatric Neurogastroenterology. Pediatric Neurogastroenterology
399
410
.
Jonathan Nzakizwanayo, Cinzia Dedi, Guy Standen, Wendy M. Macfarlane, Bhavik A. Patel & Brian V. Jones. (2015) Escherichia coli Nissle 1917 enhances bioavailability of serotonin in gut tissues through modulation of synthesis and clearance. Scientific Reports 5:1.
Crossref
Crossref
Yasuo Itomi, Toru Kawamura & Yasuhiro Tsukimi. (2015) Specific alteration of rhythm in temperature-stressed rats possess features of abdominal pain in IBS patients. Journal of Pharmacological Sciences 129:1, pages 26-30.
Crossref
Crossref
Hyun Joo Son, Kiwon Jung, Yang Hae Park, Hyo Jin Jeon, Minseok Kang, Keun Ho Ryu, Sung Soo Pyo, Helene Eutamene, Lionel Bueno & Won Suk Sun. (2014) Inhibitory effects of SKI3246, the rhizome extract of Atractylodes japonica, on visceral hypersensitivity in experimental irritable bowel syndrome rat models. Archives of Pharmacal Research 38:5, pages 642-649.
Crossref
Crossref
Daniel Hoyer. 2015. Antitargets and Drug Safety. Antitargets and Drug Safety
57
80
.
Min Jung Lee, Kang Hun Cho, Hyun Min Park, Hyun Jung Sung, Sunghak Choi & Weonbin Im. (2014) Pharmacological profile of DA-6886, a novel 5-HT4 receptor agonist to accelerate colonic motor activity in mice. European Journal of Pharmacology 735, pages 115-122.
Crossref
Crossref
David D. Manning, Cheng Guo, Zhenjun Zhang, Kristen N. Ryan, Jennifer Naginskaya, Sok Hui Choo, Liaqat Masih, William G. Earley, Jonathan D. Wierschke, Amy S. Newman, Catherine A. Brady, Nicholas M. Barnes & Peter R. Guzzo. (2014) The discovery of diazepinone-based 5-HT3 receptor partial agonists. Bioorganic & Medicinal Chemistry Letters 24:11, pages 2578-2581.
Crossref
Crossref
Gary M. Mawe & Jill M. Hoffman. (2013) Serotonin signalling in the gut—functions, dysfunctions and therapeutic targets. Nature Reviews Gastroenterology & Hepatology 10:8, pages 473-486.
Crossref
Crossref
Adam D. Farmer, Madusha Peiris & Qasim Aziz. 2013. Irritable Bowel Syndrome. Irritable Bowel Syndrome
237
262
.
Bella Zeisler & Jeffrey S. Hyams. 2013. Pediatric Neurogastroenterology. Pediatric Neurogastroenterology
367
376
.
PR Wade, JM Palmer, S McKenney, V Kenigs, K Chevalier, BA Moore, JR Mabus, PR Saunders, NH Wallace, CR Schneider, ES Kimball, HJ Breslin, W He & PJ Hornby. (2012) Modulation of gastrointestinal function by MuDelta, a mixed µ opioid receptor agonist/ µ opioid receptor antagonist. British Journal of Pharmacology 167:5, pages 1111-1125.
Crossref
Crossref
Michiel A. van Nieuwenhoven & Tessa O.C. Kilkens. (2012) The effect of acute serotonergic modulation on rectal motor function in diarrhea-predominant irritable bowel syndrome and healthy controls. European Journal of Gastroenterology & Hepatology, pages 1.
Crossref
Crossref
Lisa A. Kilpatrick, Jennifer S. Labus, Kristen Coveleskie, Christian Hammer, Gudrun Rappold, Kirsten Tillisch, Joshua A. Bueller, Brandall Suyenobu, Johana M. Jarcho, Jim A. McRoberts, Beate Niesler & Emeran A. Mayer. (2011) The HTR3A Polymorphism c. -42C>T Is Associated With Amygdala Responsiveness in Patients With Irritable Bowel Syndrome. Gastroenterology 140:7, pages 1943-1951.
Crossref
Crossref
Emeran A. MayerKirsten Tillisch. (2011) The Brain-Gut Axis in Abdominal Pain Syndromes. Annual Review of Medicine 62:1, pages 381-396.
Crossref
Crossref
David D. Manning, Christopher L. Cioffi, Alexander Usyatinsky, Kevin Fitzpatrick, Liaqat Masih, Cheng Guo, Zhenjun Zhang, Sok Hui Choo, M. Inthikhab Sikkander, Kristen N. Ryan, Jennifer Naginskaya, Carla Hassler, Svetlana Dobritsa, Jonathan D. Wierschke, William G. Earley, Amy S. Butler, Catherine A. Brady, Nicholas M. Barnes, Marlene L. Cohen & Peter R. Guzzo. (2011) Novel serotonin type 3 receptor partial agonists for the potential treatment of irritable bowel syndrome. Bioorganic & Medicinal Chemistry Letters 21:1, pages 58-61.
Crossref
Crossref
Lori A. Mahajan & Barbara Kaplan. 2011. Pediatric Gastrointestinal and Liver Disease. Pediatric Gastrointestinal and Liver Disease
66
79.e3
.
Zhicai Yang, David J. Fairfax, Jun-Ho Maeng, Liaqat Masih, Alexander Usyatinsky, Carla Hassler, Soshanna Isaacson, Kevin Fitzpatrick, Russell J. DeOrazio, Jianqing Chen, James P. Harding, Matthew Isherwood, Svetlana Dobritsa, Kevin L. Christensen, Jonathan D. Wierschke, Brian I. Bliss, Lisa H. Peterson, Cathy M. Beer, Christopher Cioffi, Michael Lynch, W. Martin Rennells, Justin J. Richards, Timothy Rust, Yuri L. Khmelnitsky, Marlene L. Cohen & David D. Manning. (2010) Discovery of 2-substituted benzoxazole carboxamides as 5-HT3 receptor antagonists. Bioorganic & Medicinal Chemistry Letters 20:22, pages 6538-6541.
Crossref
Crossref
Neehar Parikh & Colin W. Howden. (2010) The Safety of Drugs Used in Acid-related Disorders and Functional Gastrointestinal Disorders. Gastroenterology Clinics of North America 39:3, pages 529-542.
Crossref
Crossref
k. ohashi-doi, d. himaki, k. nagao, m. kawai, j. d. gale, j. b. furness & y. kurebayashi. (2010)
A selective, high affinity 5-HT
2B
receptor antagonist inhibits visceral hypersensitivity in rats
. Neurogastroenterology & Motility 22:2, pages e69-e76.
Crossref
Crossref
Alexandru Gaman, Maria Cristina Bucur & Braden Kuo. (2009) Review: Therapeutic advances in functional gastrointestinal disease: irritable bowel syndrome. Therapeutic Advances in Gastroenterology 2:3, pages 169-181.
Crossref
Crossref
Tadayoshi Mikami, Tohru Komada, Hiromi Sugimoto, Keiko Suzuki, Takashi Ohmi, Naoji Kimura, Rie Naganeo, Eriko Nakata, Keigo Nakatani, Tetsuo Toga, Hiroyuki Eda & Minoru Sakakibara. (2009) In vitro and in vivo pharmacological characterization of PF-01354082, a novel partial agonist selective for the 5-HT4 receptor. European Journal of Pharmacology 609:1-3, pages 5-12.
Crossref
Crossref
J. M. JARCHO, L. CHANG, S. M. BERMAN, B. SUYENOBU, B. D. NALIBOFF, M. D. LIEBERMAN, V. Z. AMEEN, M. A. MANDELKERN & E. A. MAYER. (2008)
Neural and psychological predictors of treatment response in irritable bowel syndrome patients with a 5-HT
3
receptor antagonist: a pilot study
. Alimentary Pharmacology & Therapeutics 28:3, pages 344-352.
Crossref
Crossref
D. T. Beattie & J. A. M. Smith. (2008) Serotonin pharmacology in the gastrointestinal tract: a review. Naunyn-Schmiedeberg's Archives of Pharmacology 377:3, pages 181-203.
Crossref
Crossref
David C.E. Bulmer, Anne-Marie Coelho & Wendy J. Winchester. (2007) Approaches to the treatment of visceral pain. Drug Discovery Today: Therapeutic Strategies 4:3, pages 171-176.
Crossref
Crossref
B. Coffin. (2007) Douleurs et syndrome de l’intestin irritable : prise en charge thérapeutique à la lumière des nouvelles pistes physiopathologiquesPain and irritable bowel syndrome : therapeutic options in light of recent pathophysiological approaches. Côlon & Rectum 1:3, pages 184-189.
Crossref
Crossref
Brian E. Lacy & L. Campbell Levy. (2007) Lubiprostone. Journal of Clinical Gastroenterology 41:4, pages 345-351.
Crossref
Crossref
E. A. MAYER, K. TILLISCH & S. BRADESI. (2006) Review article: modulation of the brain–gut axis as a therapeutic approach in gastrointestinal disease. Alimentary Pharmacology and Therapeutics 24:6, pages 919-933.
Crossref
Crossref
J. TACK, M. FRIED, L. A. HOUGHTON, J. SPICAK & G. FISHER. (2006) Systematic review: the efficacy of treatments for irritable bowel syndrome - a European perspective. Alimentary Pharmacology and Therapeutics 24:2, pages 183-205.
Crossref
Crossref
Evan S. Dellon & Yehuda Ringel. (2006) Treatment of functional diarrhea. Current Treatment Options in Gastroenterology 9:4, pages 331-342.
Crossref
Crossref
Tim Hammond & Jean-Pierre Valentin. 2006. The Process of New Drug Discovery and Development, Second Edition. The Process of New Drug Discovery and Development, Second Edition
243
289
.
Hugo Gallo-Torres, Allen Brinker & Mark Avigan. (2006) Alosetron: Ischemic Colitis and Serious Complications of Constipation. The American Journal of Gastroenterology 101:5, pages 1080-1083.
Crossref
Crossref
Timothy J Ness. (2005) Pelvic pain in women and men: recent findings. Current Opinion in Anaesthesiology 18:5, pages 555-562.
Crossref
Crossref
Benoit Coffin, Jean-Marc Sabaté & Didier Bouhassira. (2005) Douleurs et syndrome de l’intestin irritable. Gastroentérologie Clinique et Biologique 29:8-9, pages 769-771.
Crossref
Crossref
Georges Coremans. (2005)
Cilansetron: a novel, high-affinity 5-HT
3
receptor antagonist for irritable bowel syndrome with diarrhea predominance
. Therapy 2:4, pages 559-567.
Crossref
Crossref
James J Galligan. (2004) Enteric P2X receptors as potential targets for drug treatment of the irritable bowel syndrome. British Journal of Pharmacology 141:8, pages 1294-1302.
Crossref
Crossref
Colin D Rudolph & Adrian Miranda. (2004) Treatment Options for Functional Abdominal Pain. Pediatric Annals 33:2, pages 105-112.
Crossref
Crossref